Schmidt S
Neurologische Gemeinschaftspraxis Bonn, Kölnstraße 480, 53117, Bonn, Deutschland.
Nervenarzt. 2010 Oct;81(10):1231-41. doi: 10.1007/s00115-010-3040-6.
Azathioprine (AZA) is a purine analogue which has been used in the treatment of multiple sclerosis (MS) for over 30 years. After the approval of immunomodulatory drugs, such as recombinant interferon beta and glatiramer acetate, AZA now only plays a minor role in MS therapy. The results of a recently published phase III trial (CLARITY trial) involving an oral formulation of the purine analogue cladribine, a substance which is at least structurally related to AZA, may soon lead to the approval of cladribine tablets as a new oral MS therapeutic. The following overview provides a comparison of the mode of action, side-effect profile and data currently available on AZA and cladribine in the treatment of MS.
硫唑嘌呤（AZA）是一种嘌呤类似物，已用于治疗多发性硬化症（MS）30多年。在免疫调节药物，如重组干扰素β和醋酸格拉替雷获批后，AZA目前在MS治疗中仅起次要作用。最近发表的一项III期试验（CLARITY试验）结果涉及嘌呤类似物克拉屈滨的口服制剂，该物质至少在结构上与AZA相关，可能很快会使克拉屈滨片获批成为一种新的口服MS治疗药物。以下概述比较了AZA和克拉屈滨在MS治疗中的作用方式、副作用概况及现有数据。
